Profile data is unavailable for this security.
About the company
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohn’s disease, in addition to various other therapies in various stages of clinical development. The Company advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
- Revenue in USD (TTM)123.24m
- Net income in USD4.35bn
- Incorporated2014
- Employees904.00
- LocationRoivant Sciences Ltd11-12 St. James's SquareSuite 1, 3rd FloorLONDON SW1Y4LBUnited KingdomGBR
- Phone+44 207 400 3347
- Websitehttp://roivant.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Blueprint Medicines Corp | 282.21m | -288.29m | 6.60bn | 645.00 | -- | 21.25 | -- | 23.40 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
Intra-Cellular Therapies Inc | 513.93m | -110.87m | 6.94bn | 610.00 | -- | 10.68 | -- | 13.50 | -1.15 | -1.15 | 5.34 | 6.15 | 0.6996 | 1.67 | 4.83 | 842,508.20 | -15.09 | -38.27 | -17.67 | -42.77 | 92.82 | -- | -21.57 | -128.42 | 5.00 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
Jazz Pharmaceuticals PLC | 3.84bn | 330.79m | 7.06bn | 2.80k | 23.11 | 1.91 | 7.21 | 1.84 | 4.85 | 4.85 | 55.49 | 58.65 | 0.3436 | 0.6428 | 5.78 | 1,372,634.00 | 2.99 | 1.48 | 3.36 | 1.62 | 89.53 | 88.79 | 8.69 | 4.26 | 1.90 | 1.87 | 0.607 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
Vaxcyte Inc | 0.00 | -436.82m | 7.33bn | 254.00 | -- | 3.69 | -- | -- | -4.22 | -4.22 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -28.19 | -34.22 | -29.52 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
Cerevel Therapeutics Holdings Inc | 0.00 | -460.47m | 7.68bn | 355.00 | -- | 13.61 | -- | -- | -2.72 | -2.72 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -44.76 | -- | -48.20 | -- | -- | -- | -- | -- | -- | -- | 0.3745 | -- | -- | -- | -23.14 | -- | -- | -- |
Bellring Brands Inc | 1.84bn | 191.50m | 7.81bn | 420.00 | 41.64 | -- | 33.03 | 4.24 | 1.44 | 1.44 | 13.84 | -1.90 | 2.40 | 5.40 | 8.71 | 4,389,286.00 | 24.91 | 18.89 | 31.72 | -- | 32.74 | 32.44 | 10.39 | 10.10 | 1.84 | 5.07 | 1.42 | 0.00 | 21.53 | 15.03 | 101.09 | 13.80 | -18.48 | -- |
Viking Therapeutics Inc | 0.00 | -93.72m | 7.99bn | 28.00 | -- | 8.56 | -- | -- | -0.9305 | -0.9305 | 0.00 | 8.47 | 0.00 | -- | -- | 0.00 | -16.76 | -21.91 | -17.52 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
Legend Biotech Corp (ADR) | 342.80m | -465.95m | 8.07bn | 1.80k | -- | 6.95 | -- | 23.55 | -2.60 | -2.60 | 1.90 | 6.39 | 0.2297 | 9.52 | 203.86 | 190,443.30 | -31.22 | -37.71 | -37.33 | -47.19 | 52.35 | -- | -135.92 | -286.51 | 5.57 | -24.44 | 0.2233 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
Elanco Animal Health Inc | 4.37bn | -1.30bn | 8.43bn | 9.30k | -- | 1.39 | -- | 1.93 | -2.64 | -2.64 | 8.84 | 12.26 | 0.2931 | 1.21 | 4.28 | 469,354.80 | -8.74 | -3.27 | -9.65 | -3.65 | 55.28 | 54.28 | -29.83 | -11.53 | 1.96 | 0.853 | 0.4877 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
KBR Inc | 7.07bn | -258.00m | 8.86bn | 34.00k | -- | 6.31 | -- | 1.25 | -1.91 | -1.91 | 52.67 | 10.46 | 1.25 | -- | 5.56 | 207,970.60 | -4.45 | 0.4725 | -6.46 | 0.6678 | 13.86 | 12.18 | -3.58 | 0.4122 | -- | 1.17 | 0.5678 | 340.00 | 5.97 | 7.20 | -240.21 | -- | 36.31 | 11.03 |
Roivant Sciences Ltd | 123.24m | 4.35bn | 9.13bn | 904.00 | 2.24 | 1.50 | 2.14 | 74.08 | 5.07 | 5.23 | 0.1597 | 7.57 | 0.0259 | -- | 3.57 | 136,328.50 | 89.08 | -- | 105.17 | -- | 87.57 | -- | 3,439.02 | -- | 27.77 | -- | 0.0638 | -- | 10.84 | -- | -32.93 | -- | -- | -- |
Repligen Corp | 607.45m | 14.84m | 9.64bn | 1.78k | 683.31 | 4.89 | 114.10 | 15.87 | 0.2524 | 0.2524 | 10.74 | 35.29 | 0.2255 | 1.43 | 4.87 | 340,689.80 | 0.551 | 4.38 | 0.6179 | 5.03 | 47.73 | 55.43 | 2.44 | 15.91 | 5.24 | -- | 0.2284 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
Exact Sciences Corp | 2.53bn | -240.23m | 9.96bn | 6.50k | -- | 3.17 | -- | 3.93 | -1.32 | -1.32 | 13.93 | 17.04 | 0.3998 | 5.28 | 11.96 | 389,975.40 | -3.79 | -9.71 | -4.13 | -10.60 | 73.67 | 74.10 | -9.48 | -28.21 | 1.45 | -- | 0.4323 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
Catalent Inc | 4.14bn | -1.18bn | 10.05bn | 17.80k | -- | 2.77 | -- | 2.43 | -6.48 | -6.48 | 22.69 | 20.06 | 0.3993 | 4.36 | 2.87 | 232,303.40 | -11.36 | 2.88 | -12.91 | 3.26 | 18.96 | 31.03 | -28.44 | 6.35 | 1.74 | -0.4346 | 0.5797 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
Holder | Shares | % Held |
---|---|---|
Viking Global Investors LPas of 31 Dec 2023 | 69.37m | 8.61% |
QVT Financial LPas of 07 Mar 2024 | 66.72m | 8.28% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 36.97m | 4.59% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 32.10m | 3.98% |
Rubric Capital Management LPas of 31 Mar 2024 | 20.00m | 2.48% |
Morgan Stanley Investment Management, Inc.as of 31 Dec 2023 | 18.51m | 2.30% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 13.73m | 1.70% |
Wellington Management Co. LLPas of 31 Dec 2023 | 13.64m | 1.69% |
Two Seas Capital LPas of 31 Dec 2023 | 8.51m | 1.06% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 7.63m | 0.95% |